舒血宁注射液联合倍他司汀治疗椎基底动脉供血不足眩晕的临床效果及对血液流变学和预后的影响  

Clinical Effect of Shuxuening Combined with Betahistine in the Treatment of Vertigo Caused by Vertebrobasilar Artery Insufficiency and Its Influence on Hemorheology and Prognosis

作　　者：孙英[1] 刘影 孙晓羽 徐雅楠 SUN Ying;LIU Ying;SUN Xiao-yu;XU Ya-nan(the Sixth Department of Neurology,People's Hospital of Liaoning Province,Shenyang 110016,China)

机构地区：[1]辽宁省人民医院神经内六科,沈阳110016

出　　处：《解放军医药杂志》2021年第3期104-107,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：辽宁省自然科学基金(20180550213)。

摘　　要：目的探讨舒血宁注射液联合倍他司汀治疗椎基底动脉供血不足眩晕的临床效果及对血液流变学和预后的影响。方法选取2018年1月—2019年6月我院收治的147例椎基底动脉供血不足眩晕患者作为研究对象,根据治疗方法的不同分为研究组77例和对照组70例,对照组予倍他司汀治疗,研究组予舒血宁注射液联合倍他司汀治疗。对比2组的临床疗效、血液流变学指标、生活质量评价量表(short from 36 questionnaire,SF-36)评分、生活满意度量表(satisfaction with life scale,SWLS)评分及不良反应。结果研究组总有效率显著高于对照组(P<0.01)。治疗后,2组红细胞压积、红细胞沉降率、血浆黏度、全血高切黏度、全血低切黏度水平明显降低,且研究组显著低于对照组,差异有统计学意义(P<0.05或P<0.01);治疗后,2组SF-36评分较治疗前显著升高,研究组显著高于对照组,差异有统计学意义(P<0.05或P<0.01);研究组治疗后1、3、6、12个月的SWLS评分均显著高于对照组(P<0.01);2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论舒血宁注射液联合倍他司汀治疗可有效提升椎基底动脉供血不足眩晕患者的临床效果,改善血液流变学,有利于患者预后,且安全性高。Objective To explore the clinical effect of Shuxuening combined with Betahistine in the treatment of patients with vertigo caused by vertebrobasilar artery insufficiency(VBI),and its influence on hemorheology and prognosis.Methods A total of 147 patients with vertigo caused by VBI admitted to our hospital from January 2018 to June 2019 were enrolled in this study.According to the different treatment methods,they were divided into research group(n=77)and control group(n=70).The control group was treated with betahistine,and the research group was treated with Shuxuening combined with betahistine.The clinical efficacy,blood rheology index,score of quality of life by SF-36,satisfaction with life scale(SWLS)score and adverse reactions of the two groups were compared.Results The total effective rate of the research group was significantly higher than that of the control group(P<0.01).After treatment,the levels of hematocrit(HCT),erythrocyte sedimentation rate(ESR),plasma viscosity(PSV),whole blood high shear viscosity(HSV),and whole blood low shear viscosity(LSV)were significantly reduced in the two groups,and the levels in the research group were significantly lower than those in the control group(P<0.05 or P<0.01).After treatment,the scores of SF-36 scale in the two groups were significantly higher than those before treatment,and the scores were significantly higher in the research group than in the control group(P<0.05 or P<0.01).The SWLS scores of the research group were significantly higher than those of the control group at 1,3,6 and 12 months after treatment(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Shuxuening combined with betahistine can effectively improve the clinical efficacy of patients with vertigo caused by VBI,improve hemorheology,and is conductive to the prognosis of patients with high safety.

关 键 词：舒血宁 倍他司汀 眩晕 椎底动脉供血不足 血液流变学 生活质量 

分 类 号：R743.9[医药卫生—神经病学与精神病学]